Concurrently, post-Bevacizumab treatment, upregulation of VEGF-C/D-VEGFR3 signaling led to a 35% increase in lymphatic vessel density, facilitating tumor metastasis via the lymphatic system (Li et al., 2019). This evidence concerns the gene FLT4 and neoplasm.